Short Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Decreases By 10.7%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,500,000 shares, a decrease of 10.7% from the March 31st total of 2,800,000 shares. Based on an average daily volume of 836,100 shares, the days-to-cover ratio is currently 3.0 days.

Alnylam Pharmaceuticals Trading Down 0.3 %

ALNY opened at $143.31 on Monday. The stock has a market cap of $18.05 billion, a price-to-earnings ratio of -40.26 and a beta of 0.39. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $218.88. The stock has a fifty day moving average price of $150.21 and a 200 day moving average price of $165.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.68) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ALNY shares. Royal Bank of Canada reiterated an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Finally, Chardan Capital reduced their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $215.88.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. ANTIPODES PARTNERS Ltd lifted its position in shares of Alnylam Pharmaceuticals by 69.1% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after purchasing an additional 77,307 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock worth $2,064,425,000 after purchasing an additional 30,608 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 630.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after buying an additional 22,580 shares during the period. Asset Management One Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 41.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock valued at $13,569,000 after buying an additional 20,268 shares during the period. Finally, Royal London Asset Management Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 86.7% in the third quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock valued at $54,303,000 after buying an additional 142,357 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.